dr. apolo on toxicity challenges with checkpoint inhibitors in bladder cancer
Published 6 years ago • 279 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:32
dr. apolo on managing toxicities of checkpoint inhibitors in bladder cancer
-
0:46
dr. apolo on managing toxicities with checkpoint inhibitors in bladder cancer
-
0:54
dr. o’donnell on challenges with pd-l1 testing in bladder cancer
-
1:35
dr. plimack on choosing a checkpoint inhibitor in bladder cancer
-
1:06
dr. gulley on checkpoint inhibitors in bladder cancer
-
1:14
how can we continue the success of checkpoint inhibitors for bladder cancer treatment?
-
1:13
dr. bellmunt on challenges with immunotherapy in bladder cancer
-
1:51
dr. grivas on checkpoint inhibitors in localized bladder cancer
-
0:55
dr. plimack on frontline checkpoint inhibitors in bladder cancer
-
1:06
dr. o'donnell compares checkpoint inhibitors in bladder cancer
-
4:51
practical considerations with checkpoint inhibitors in bladder cancer
-
1:01
dr. andrea apolo on treatment challenges in metastatic bladder cancer
-
1:14
dr. plimack on second-line checkpoint inhibitors in bladder cancer
-
1:48
dr. friedlander on checkpoint inhibitors in second-line bladder cancer treatment
-
6:44
immunotherapy toxicity management in bladder cancer
-
1:28
dr. flaig on immune checkpoint inhibitors in advanced bladder cancer
-
0:56
dr. petrylak on ongoing investigations of checkpoint inhibition in bladder cancer
-
6:00
use of immune checkpoint inhibitors for bladder cancer
-
10:44
earlier use of immune checkpoint inhibitors to adjuvant and non muscle invasive bladder cancer